11 a.m.–12 p.m.
Background on Current Mechanistic Understanding of Common ToxicitiesSumit Subudhi, MD, PhD – The University of Texas MD Anderson Cancer Center
Management of Common and Challenging Immune-Related Adverse EventsMehmet Altan, MD – The University of Texas MD Anderson Cancer CenterNicolas L. Palaskas, MD – The University of Texas MD Anderson Cancer CenterYinghong (Mimi) Wang, MD, PhD, MSc – The University of Texas MD Anderson Cancer Center
Management of Checkpoint Inhibitor Complications in Special Cancer PopulationMaen Abdelrahim, MD, PhD, PharmD – Houston MethodistNoha Abdel-Wahab, MD, PhD – The University of Texas MD Anderson Cancer Center
Future Directions for Research and New Management Approaches in Immunotherapy ToxicitiesAdi Diab, MD – The University of Texas MD Anderson Cancer CenterJennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center
Cancer Immunotherapy in PracticeMichelle Rohlfs, APRN, FNP-BC, AOCNP – The University of Texas MD Anderson Cancer Center
Faculty PanelMaen Abdelrahim, MD, PhD, PharmD – Houston MethodistNoha Abdel-Wahab, MD, PhD – The University of Texas MD Anderson Cancer CenterMehmet Altan, MD – The University of Texas MD Anderson Cancer CenterAdi Diab, MD – The University of Texas MD Anderson Cancer CenterNicolas Palaskas, MD – The University of Texas MD Anderson Cancer CenterMichelle Rohlfs, APRN, FNP-BC, AOCNP – The University of Texas MD Anderson Cancer CenterSumit Subudhi, MD, PhD – The University of Texas MD Anderson Cancer CenterVan Anh Trinh, PharmD, BCOP – The University of Texas MD Anderson Cancer CenterYinghong (Mimi) Wang, MD, PhD, MS – The University of Texas MD Anderson Cancer CenterJennifer A. Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center
4:25 – 4:30 p.m.
Program Learning Objectives
Case Study Submission Information:To submit closed/past case studies for live expert panel feedback, please indicate your interest in the checkbox in program registration and SITC staff will follow up with you through email with further instruction.Target AudienceThe Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute of Medicine designates this continuing education activity for 4.0 contact hours (0.40 CEUs) of the Accreditation Council for Pharmacy Education.
The maximum number of hours awarded for this Continuing Nursing Education activity is 4.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.
Americans with Disabilities ActEvent staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email firstname.lastname@example.org.
The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 1/19/2022)
The 2021-2022 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Association of Community Cancer Centers, Advances Practitioner Society for Hematology and Oncology, and Hematology/Oncology Pharmacy Association. This program is provided in collaboration with the American Academy of Emergency Medicine.
Technology Information and Policy
At SITC’s Advances in Cancer ImmunotherapyTM: A Focus on Toxicity Management Live Event, our goal is to have a safe and meaningful in-person experience. We will be adhering to the local safety guidelines and regulations. For the latest information on requirements for Houston, click here. In addition, SITC in-person meetings will have the following safety measures in place:
Proof of full vaccination for COVID-19 will be required for program attendees. In-person attendees can upload proof of vaccination here.
SITC strongly recommends masks to be worn indoors for attendees.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com